TABLE 5.
Summarized MICs (μg/mL) of 11a and 11bb.
| (A) MICs of 11a and 11b against fungi (Subedi et al., 2020b) | |||||||||||||||
| Compound | A | B | C | D | E | F | G | H | I | J | K | L | |||
| 11a | 32 | 4 | 8 | 8 | 4 | 4 | 8 | 8 | 16 | 16 | 4 | 4 | |||
| 11b | 16 | 4 | 8 | 8 | 4 | 4 | 8 | 8 | 8 | 16 | 0.5 | 0.5 | |||
| Voriconazole | 1 | 32 | ≥256 | 0.125 | 0.125 | 8 | NDa | ND | ND | ND | ND | ND | |||
|
| |||||||||||||||
|
(B) MICs of 11a and 11b against clinical fungal isolates (Subedi et al., 2020b)
| |||||||||||||||
| Compound | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O |
|
| |||||||||||||||
| 11a | 8 | 8 | 8 | 4 | 4 | 8 | 8 | 16 | 2 | 4 | 8 | 2 | 4 | 4 | 4 |
| 11b | 4 | 8 | 8 | 4 | 0.5 | 1 | 4 | 8 | 2 | 2 | 2 | 8 | 8 | 4 | 2 |
| fluconazole | 2 | 32 | NDa | >64 | >64 | >64 | ND | ND | ND | ND | ND | ND | ND | 0.06 | 0.125 |
(A) A: A. flavus, B: F. graminearium B4-5A, C: C. albicans 64124, D: C. albicans MYA2876, E: C. neoformans H99, F: R. pilimanae; G: C. albicans B-311, H: C. rugosa 95-967, I: C. parapsolis Cas08-0490 (azole resistant), J: C. tropicalis 95-41, K: C. auris DI17-48, L: C. auris DI17-47.
aND, not determined.
(B) A: C. parapsilosis (QC ATCC 22019), B: C. krusei (QC ATCC 6258), C: Paecilomyces variotii (QC), D: C. albicans (CA3), E: C. auris (DI17-47), F: C. auris (DI17-46), G: A. fumigatus (AF1), H: A. fumigatus (AF3), I: Lomentospora prolificans (LP1), J: Scedosporium apiospermum (SA1), K: Scedosporium boydii (SB1), L: Apophysomyces (APO1), M: Apophysomyces (APO2), N: Blastomyces dermatitidis (BD1), O: B. dermatitidis (BD3).
aND, not determined.
bConducted by The University of Texas Health Science Center at San Antonio, contracted through NIH’s Division of Microbiology and Infectious Diseases (DMID) of NIAID.